CLINICAL, IMMUNOLOGICAL CRITERIA AND LABORATORY MARKERS OF ATYPICAL CHRONIC ACTIVE INFECTION CAUSED BY THE EPSTEIN-BARR VIRUS

Cover Page
  • Authors: Nesterova I.V.1,2, Khalturina Е.О.3,2
  • Affiliations:
    1. Federal State Budget Educational Institution of Higher Professional Education “Peoples' Friendship University of Russia” of Ministry of Education and Science of Russia
    2. Clinical and Diagnostic Center “MEDCI at Belorusskaya”
    3. I.M. Sechenov First Moscow State Medical University (Sechenov University)
  • Issue: Vol 21, No 2 (2018)
  • Pages: 170-177
  • Section: ORIGINAL ARTICLES
  • URL: https://rusimmun.ru/jour/article/view/70
  • ID: 70

Cite item

Full Text

Abstract

Today, an atypical chronic active infection caused by herpesviruses and, in particular, the Epstein-Barr virus is polysymptomatic and polysyndromic. It is also a difficult to diagnose and poorly understood disease. Patients suffering from this disease often turn to specialists of various profiles. However, the disease is often not diagnosed and the patients remain without a correct diagnosis and, consequently, without an adequate therapy. The revealed clinical and immunological criteria and laboratory markers of this persistent viral infection allowed developing a diagnostic algorithm that is used to establish a correct diagnosis of atypical chronic active infection caused by the Epstein-Barr virus. In addition, features of the immune system functioning and interferon status in this infection have been detected. The main features are the defects of the induced production of IFNα and IFNγ, deficiency of cytotoxic T lymphocytes, of natural killer cells, including EKT, and / or inadequate absence of activation, neutropenia. In general, the revealed clinical diagnostic and immunopathogenetic features of the course of atypical chronic active infection caused by the Epstein-Barr virus, as well as the developed algorithm, will further allow to create the concept of an individualized / personified, complex etio- and immunopathogenetic, targeted therapy of this atypical, often invalidating viral infection. The development of methods for the rehabilitation of the body's antiviral protection system and the interferon system will lead to a significant reduction or complete suppression of the replicative activity of EBV. That will allow the return of control of the immune system, as well as interferon systems over EBV and other herpes-viral infections.

About the authors

I. V. Nesterova

Federal State Budget Educational Institution of Higher Professional Education “Peoples' Friendship University of Russia” of Ministry of Education and Science of Russia; Clinical and Diagnostic Center “MEDCI at Belorusskaya”

Author for correspondence.
Email: inesterova1@yandex.ru

MD (Medicine), Professor, Professor of the Department of Allergology and Immunology

117513, Moscow, Leninsky prospect, 123-1.

Russian Federation

Е. О. Khalturina

I.M. Sechenov First Moscow State Medical University (Sechenov University); Clinical and Diagnostic Center “MEDCI at Belorusskaya”

Email: fake@neicon.ru

PhD, docent of Department of Microbiology, Virology and Immunology

Moscow

Russian Federation

References

  1. Babcock J.G., Hochberg D., Thorley-Lawson A.D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000, 13, 497–506.
  2. Hislop A.D., Taylor G.S., Sauce D., Rickinson A.B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007, 25, 587–617.
  3. Kuzushima K., Matsuoka H. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection. J Med Virol. 2001, 64, 141–8.
  4. Lusso P. HHV-6 and the immune system: Mechanisms of immunomodulation and viral escape. J Clin Virol. 2006, 37(Suppl 1), 4–10.
  5. Merlo A., Turrini R., Dolcetti R., Martorelli D., Muraro E., Comoli P., Rosato A. The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010, 95(10), 1769–1777.
  6. Ning S. Innate immune modulation in EBV infection. Herpesviridae 2011, 2(1), 1.
  7. Pizzigallo E., Racciatti D., Gorgoretti V. EBV Chronic Infections. Mediterr J Hematol Infect Dis. 2010, 2(1), e2010022.
  8. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen.Virol. 2008, 89, 1–47.
  9. Wu L., Fossum E., Joo C.H., Inn K.S., Shin Y.C., Johannsen E., Hutt-Fletcher L.M., Hass J., Jung J.U. Epstein-Barr virus LF2: an antagonist to type I interferon. J Virol. 2009, 83(2), 1140–1146.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Nesterova I.V., Khalturina Е.О.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies